or Try an Advanced Search...

    Technical Analysis for RZLT - Rezolute, Inc.

    Grade Last Price % Change Price Change
    A 5.50 0.36% 0.02
    RZLT closed up 0.36 percent on Friday, November 1, 2024, on 63 percent of normal volume.
    Earnings due: Nov 11
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical RZLT trend table...
    Date Alert Name Type % Chg
    180 Bullish Setup Bullish Swing Setup 0.36%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.36%
    Pocket Pivot Bullish Swing Setup 0.36%
    Gapped Down Weakness 0.36%
    Upper Bollinger Band Walk Strength 1.10%
    Overbought Stochastic Strength 1.10%
    Pocket Pivot Bullish Swing Setup -3.17%
    NR7 Range Contraction -3.17%
    Upper Bollinger Band Walk Strength -3.17%
    Inside Day Range Contraction -3.17%
    Older End-of-Day Signals for RZLT ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 22 hours ago
    Down 1% about 23 hours ago
    10 DMA Support about 23 hours ago
    Fell Below 10 DMA about 23 hours ago
    Bullish 180 Entry about 24 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    RZLT Chart by TradingView
    Basic chart:

    Profile

    Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. Its products include RZ358, a human monoclonal antibody that is in Phase II clinical trial for the treatment of congenital hyperinsulinism, a devastating ultra-orphan pediatric disease; and RZ402, a plasma kallikrein inhibitor, which is in late stage preclinical program for the treatment of diabetic macular edema. It also develops AB101, a human recombinant insulin, which is in Phase I clinical trial for the treatment of patients with type 1 and type 2 diabetes mellitus. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Life Sciences Diabetes Cancer Treatment Monoclonal Antibody Metabolic Disease Insulin Specialty Drugs Diabetes Mellitus Diabetic Retinopathy Macular Edema Diabetic Macular Edema Kallikrein Plasma Kallikrein

    Is RZLT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 17 With 62% ownership, Rezolute, Inc. (NASDAQ:RZLT) boasts of strong institutional backing
    Sep 19 Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
    Sep 9 Rezolute rises as FDA lifts clinical hold on hyperinsulinism therapy
    Sep 9 FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
    Sep 3 Pleasing Signs As A Number Of Insiders Buy Rezolute Stock
    Aug 27 Rezolute to Participate in Upcoming Investor Conferences
    Aug 5 Rezolute gets FDA okay for Phase 3 ersodetug registrational study
    Aug 5 Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
    Jul 31 Rezolute to Participate in the BTIG Virtual Biotechnology Conference
    Jun 27 Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
    See more RZLT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.0999
    52 Week Low 0.72
    Average Volume 398,551
    200-Day Moving Average 3.53
    50-Day Moving Average 4.96
    20-Day Moving Average 5.12
    10-Day Moving Average 5.46
    Average True Range 0.29
    RSI (14) 60.63
    ADX 23.49
    +DI 27.55
    -DI 16.34
    Chandelier Exit (Long, 3 ATRs) 5.05
    Chandelier Exit (Short, 3 ATRs) 5.42
    Upper Bollinger Bands 5.88
    Lower Bollinger Band 4.35
    Percent B (%b) 0.75
    BandWidth 29.96
    MACD Line 0.21
    MACD Signal Line 0.16
    MACD Histogram 0.0411
    Fundamentals Value
    Market Cap 217.94 Million
    Num Shares 39.6 Million
    EPS -1.10
    Price-to-Earnings (P/E) Ratio -5.00
    Price-to-Sales 0.00
    Price-to-Book 0.38
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.88
    Resistance 3 (R3) 5.88 5.75 5.81
    Resistance 2 (R2) 5.75 5.66 5.75 5.79
    Resistance 1 (R1) 5.63 5.60 5.69 5.63 5.77
    Pivot Point 5.50 5.50 5.54 5.50 5.50
    Support 1 (S1) 5.38 5.41 5.44 5.38 5.23
    Support 2 (S2) 5.25 5.35 5.25 5.21
    Support 3 (S3) 5.13 5.25 5.19
    Support 4 (S4) 5.13